Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report

Journal of Medical Case Reports

Naveen S Vasudev⁵  Alan Paul²  Michael Weston¹  Patricia Harnden⁴  Sebastian Trainor³  Ioannis Trigonis³  Satinder P Jagdev³  Christy Ralph³  Luis Daverede³ 

[1] Department of Radiology, St James’s Institute of Oncology, Leeds LS9 7TF, UK;Department of Urological Oncology, Paul Sykes Centre, St James’s University Hospital, Leeds LS9 7TF, UK;Department of Medical Oncology, St James’s Institute of Oncology, Leeds LS9 7TF, UK;Department of Pathology, St James’s Institute of Oncology, Leeds LS9 7TF, UK;Cancer Research UK Centre, Leeds Institute of Cancer Studies and Pathology, Leeds LS9 7TF, UK

关键词: PSA;    Complete response;    Chemotherapy;    Castrate-resistant prostate cancer;   

Others  :  822251
DOI  :  10.1186/1752-1947-8-122

 received in 2013-08-14, accepted in 2014-02-14,  发布年份 2014

【 摘 要 】

Introduction

Although treatment options for men with metastatic castrate-resistant prostate cancer have improved in recent years, the outlook for patients remains poor, with overall survival in the region of 2 years. Response rates with chemotherapy are modest and disease progression is usually observed within months of stopping treatment.

Case presentation

We present a case of a 72-year-old White man of British origin with metastatic castrate-resistant prostate cancer with bulky lymphadenopathy and a serum prostate-specific antigen of 295μg/L. He received treatment with docetaxel chemotherapy plus prednisolone, but received just 3 cycles before treatment was stopped due to toxicity and lack of response (prostate-specific antigen was 276μg/L 4 weeks after the last dose and there was a confirmed stable appearance on computed tomography scan). Unexpectedly, at follow-up 4 months later, the patient was clinically better; his prostate-specific antigen had dramatically improved to 4.1μg/L and a re-staging computed tomography scan revealed complete resolution of his bulky lymphadenopathy. At the time, he was receiving a luteinising hormone-releasing hormone analogue but no other disease-modulating treatment. He remains well and asymptomatic, with his most recent serum prostate-specific antigen measuring 0.14μg/L, 18 months after last receiving chemotherapy.

Conclusion

We report a case of complete and durable regression of metastatic castrate-resistant prostate cancer following palliative chemotherapy which, to the best of our knowledge, has not previously been reported in the literature.

【 授权许可】

   
2014 Daverede et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G: The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008, 15:3866-3871.
• [2]Cancer Research UK: Prostate cancer statistics. 2010. http://info.cancerresearchuk.org/cancerstats/types/prostate/ webcite
• [3]Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Eng J Med 2004, 351:1502-1512.
• [4]de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, et al.: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
• [5]Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
• [6]Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M, VENICE investigators: Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013, 4:760-768.
• [7]Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
• [8]Hanninen M, Venner P, North S: A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can Urol Assoc J 2009, 3:369-374.
• [9]Goc A, Kochuparambil ST, Al-Husein B, Al-Azayzih A, Mohammad S, Somanath PR: Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer 2012, 12:409. BioMed Central Full Text
• [10]Dale KM, Coleman CI, Henyan NN, Kluger J, White CM: Statins and cancer risk: a meta-analysis. JAMA 2006, 295:74-80.
• [11]Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL: Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 2012, 30:3540-3544.
• [12]Kundranda MN, Muslimani A, Daw HA, Spiro TP: Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal. Clin Genitourin Cancer 2007, 5:401-402.
• [13]Bissada NK, Kaczmarek AT: Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol 1995, 153:1944-1945.